SDC1 and Splenomegaly: Consistent with a reduction in CD138+ cells and auto-antibodies, both lymphadenopathy and splenomegaly were reduced in CGS-21680-treated MRL/lpr mice compared to vehicle-treated controls (Fig. 3b).